Anita H. Clayton, MD

University of Virginia School of Medicine, Charlottesville, Virginia

27Articles
138.1KReads
2001–2026Active
108Collaborators
300Citations

About

Anita H. Clayton, MD, affiliated with the University of Virginia School of Medicine, has published extensively on topics including major depressive disorder, sexual dysfunction, psychopharmacology, addiction, anxiety, sleep, and women's mental health. Her work covers clinical evaluations of sexual function related to antidepressant use, mechanisms of antidepressant action, and treatment considerations for depression in perimenopausal and postmenopausal women. She has contributed to research on neuroactive steroids, GABA pathways, and substance misuse in psychiatric populations. Clayton's publications span from 2001 to 2026 and include collaborations with authors such as Madhukar H. Trivedi and Angel L. Montejo.

Publications

Original Research

Evaluation of Sexual Function With Adjunctive Lumateperone in Major Depressive Disorder

September 2, 2026

Adjunctive lumateperone 42 mg did not worsen sexual functioning and was not associated with treatment-related sexual dysfunction.

Anita H. Clayton, Willie R. Earley, Susan G. Kozauer, et al

ASCP Corner

When Do Physical Symptoms After Antidepressant Cessation Reflect Pharmacodynamic versus Non-pharmacodynamic Clinical Phenomena?

August 6, 2026

Focuses on descriptive symptom phenomenology and strategies to minimize discomfort during antidepressant cessation, with possible explanations for unusual, delayed, or protracted symptoms in patients for whom non-pharmacodynamic features may...

Joseph F. Goldberg, M. Lynn Crismon, David W. Goodman, et al

Original Research

Gepirone-ER and Sexual Function in Patients with MDD

October 21, 2024

Rates of sexual side effects and treatment-emergent sexual dysfunction with gepirone-ER were similar to placebo and lower than sexual side effects reported for SSRIs.

Tierney K. Lorenz, Mary F. Johnson, Anita H. Clayton

Supplement Article

The GABA Pathway and New Clinical Trial Data in MDD and PPD

March 16, 2023

Studies evaluating neuroactive steroid GABA-A receptor positive allosteric modulators demonstrate promising results for the treatment of MDD and PPD.

Kristina M. Deligiannidis, Anita H. Clayton

Original Research

Effect of Zuranolone vs Placebo in MDD

February 20, 2023

This phase 3 RCT found significant improvement in depressive symptoms with zuranolone beginning at day 3 of treatment.

Anita H. Clayton, Robert Lasser, Indrani Nandy, et al

Original Research

Lurasidone and Sexual Function

August 7, 2018

As you probably know, sexual dysfunction is a common side effect of antidepressants and antipsychotics. This secondary analysis of an RCT examines whether the atypical antipsychotic lurasidone was linked...

Andrei Pikalov, Anita H. Clayton, Joyce Tsai, et al

Original Research

Desvenlafaxine 50 and 100 mg/d Versus Placebo for the Treatment of Major Depressive Disorder: A Phase 4, Randomized Controlled Trial

October 28, 2014

Michael E. Thase, Anita H. Clayton, Kristen Focht, et al

Article

Prevalence of Substance Misuse in New Patients in an Outpatient Psychiatry Clinic Using a Prescription Monitoring Program

January 2, 2014

The purpose of this study was to investigate the value of a prescription monitoring program in identifying prescription drug misuse among patients presenting to a resident physicians' outpatient psychiatry...

Anita H. Clayton, Elle M. Sowa, Jonathan C. Fellers, et al

Article

Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

October 15, 2013

Susan G. Kornstein, Philip T. Ninan, Boadie W. Dunlop, et al

Educational Activity

Understanding Antidepressant Mechanism of Action and Its Effect on Efficacy and Safety

March 15, 2012

Anita H. Clayton

Article

Depression or Menopause? Presentation and Management of Major Depressive Disorder in Perimenopausal and Postmenopausal Women

February 18, 2010

In this review article, examine the risk of depression onset in perimenopausal and postmenopausal women and find out how to screen for and manage depression in your perimenopausal and...

Philip T. Ninan, Anita H. Clayton

Article

Distressing Sexual Problems in United States Women Revisited: Prevalence After Accounting for Depression

December 15, 2009

Anita H. Clayton, Catherine B. Johannes, Dawn M. Odom, et al

1 2 3 »

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Anita H. Clayton, MD

About

Publications

Evaluation of Sexual Function With Adjunctive Lumateperone in Major Depressive Disorder

When Do Physical Symptoms After Antidepressant Cessation Reflect Pharmacodynamic versus Non-pharmacodynamic Clinical Phenomena?

Gepirone-ER and Sexual Function in Patients with MDD

The GABA Pathway and New Clinical Trial Data in MDD and PPD

Effect of Zuranolone vs Placebo in MDD

Lurasidone and Sexual Function

Desvenlafaxine 50 and 100 mg/d Versus Placebo for the Treatment of Major Depressive Disorder: A Phase 4, Randomized Controlled Trial

Prevalence of Substance Misuse in New Patients in an Outpatient Psychiatry Clinic Using a Prescription Monitoring Program

Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

Understanding Antidepressant Mechanism of Action and Its Effect on Efficacy and Safety

Depression or Menopause? Presentation and Management of Major Depressive Disorder in Perimenopausal and Postmenopausal Women

Distressing Sexual Problems in United States Women Revisited: Prevalence After Accounting for Depression

ELSEWHERE:

FOLLOW US:

About

Publications

Evaluation of Sexual Function With Adjunctive Lumateperone in Major Depressive Disorder

When Do Physical Symptoms After Antidepressant Cessation Reflect Pharmacodynamic versus Non-pharmacodynamic Clinical Phenomena?

Gepirone-ER and Sexual Function in Patients with MDD

The GABA Pathway and New Clinical Trial Data in MDD and PPD

Effect of Zuranolone vs Placebo in MDD

Lurasidone and Sexual Function

Desvenlafaxine 50 and 100 mg/d Versus Placebo for the Treatment of Major Depressive Disorder: A Phase 4, Randomized Controlled Trial

Prevalence of Substance Misuse in New Patients in an Outpatient Psychiatry Clinic Using a Prescription Monitoring Program

Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

Understanding Antidepressant Mechanism of Action and Its Effect on Efficacy and Safety

Depression or Menopause? Presentation and Management of Major Depressive Disorder in Perimenopausal and Postmenopausal Women

Distressing Sexual Problems in United States Women Revisited: Prevalence After Accounting for Depression

Learn More About Psychedelics in Psychiatry

Subscribe to readmore articles

Subscribe to read
more articles